Twist Bioscience to Host Virtual Biopharma Analyst & Investor Event on October 23, 2020
October 13 2020 - 7:00AM
Business Wire
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced that it will host a
Twist Biopharma Analyst & Investor Event on Friday, October 23,
2020. The event is scheduled to take place from 11:00 a.m. – 1:00
p.m. ET in a virtual format.
The event will include an overview of Twist Biopharma and its
unique approach to antibody discovery facilitated by its precisely
synthetized “Library of Libraries” and antibody optimization
solution. Twist Biopharma enables its partners to apply next
generation drug development to some of the world’s most intractable
health challenges.
The program will also feature a series of presentations by three
Twist Biopharma customers:
- Takeda Pharmaceutical Company Robert Mabry, Ph.D., Head of
Global Biologics Research
- Invetx Jürgen Horn, Ph.D., Founder and Chief Executive
Officer
- Neogene Therapeutics Carsten Linnemann, Ph.D., President and
Chief Executive Officer
The presentations will be followed by a Q&A session.
The call and accompanying slides will be webcast live on the
company's website at https://investors.twistbioscience.com/events-and-presentations/events.
To listen to the conference call live, please dial (888) 317-6003
(domestic) or (412) 317-6061 (international) and reference
conference ID number 3930359.
A replay of the conference call will be accessible approximately
one hour after its completion through November 6, 2020 by dialing
(877) 344-7529 (domestic) or (412) 317-0088 (international) and
referencing replay access code 10148526. A webcast of the call will
also be archived for 90 days under the Investor Relations section
of the company's website at https://investors.twistbioscience.com/events-and-presentations/events.
About Twist Biopharma
By leveraging its unique ability to manufacture DNA at scale,
Twist Biopharma can construct proprietary antibody libraries
precisely designed to match sequences that occur in the human body.
This Library of Libraries gives Twist Biopharma partners an
integral and unbiased resource for antibody therapeutic discovery
and optimization. This precise and rational approach to library
fabrication combined with sophisticated bioinformatics and software
expertise expedites antibody discovery by decreasing risk,
increasing speed, and lowering the failure rate for antibody
therapeutic development.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn |
YouTube
CONTACTS
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201013005385/en/
Investor Contact: Argot Partners Maeve Conneighton 212-600-1902
maeve@argotpartners.com
Media Contact: Angela Bitting 925- 202-6211
media@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024